This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Corneal Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Y. Jerold Gordon, MD; Trinita Araullo-Cruz, PhD; Eric G. Romanowski, MS

Arch Ophthalmol. 1998;116:900-905.

Objective  To evaluate the antiviral activity of topical diclofenac sodium (Voltaren Ophthalmic) and ketorolac tromethamine (Acular) (2 nonsteroidal anti-inflammatory drugs [NSAIDs]) on adenoviral replication in vitro and in the adenovirus (Ad) 5 McEwen–New Zealand rabbit ocular model.

Methods  The 50% inhibitory concentration of ketorolac and diclofenac and their respective preservative components were determined for common ocular adenoviral serotypes (Ad8, Ad19, Ad1, and Ad5). In a series of experiments, Ad5 McEwen–inoculated New Zealand rabbit eyes were treated topically 4 times daily for 18 days with either ketorolac, diclofenac, prednisolone acetate (Pred Forte), or control vehicle (Comfort Tears).

Main Outcome Measures  Outcome measures included serial ocular tear film titers and the formation of subepithelial immune corneal infiltrates.

Results  In vitro, neither ketorolac nor diclofenac demonstrated significant inhibitory activity against Ad1, Ad5, Ad8, or Ad19. In the rabbit model, there were no statistically significant differences among ketorolac, diclofenac, and the control vehicle with respect to viral replication or the formation of subepithelial immune infiltrates. In contrast, 1% prednisolone prolonged viral shedding and inhibited immune infiltrates (P<.001 for both).

Conclusions  Our experimental study suggests that treatment of epidemic keratoconjunctivitis with topical NSAIDs may be a safer alternative than topical steroids. Only controlled clinical trials can determine whether topical NSAIDs can provide symptomatic relief and not interfere with normal viral clearance.

From the Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pa.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The In Vitro and In Vivo Evaluation of ddC as a Topical Antiviral for Ocular Adenovirus Infections
Romanowski et al.
IOVS 2009;50:5295-5299.
ABSTRACT | FULL TEXT  

Efficacy of Topical Immunoglobulins against Experimental Adenoviral Ocular Infection
Nwanegbo et al.
IOVS 2007;48:4171-4176.
ABSTRACT | FULL TEXT  

Effects of Diclofenac or Ketorolac on the Inhibitory Activity of Cidofovir in the Ad5/NZW Rabbit Model
Romanowski and Gordon
IOVS 2001;42:158-162.
ABSTRACT | FULL TEXT  

Efficacy of Topical Cidofovir on Multiple Adenoviral Serotypes in the New Zealand Rabbit Ocular Model
Romanowski and Gordon
IOVS 2000;41:460-463.
ABSTRACT | FULL TEXT